UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

November 13, 2017 (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-11353	13-3757370
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
250 South Main Street		
358 South Main Street,		
Burlington, North Carolina	27215	336-229-1127
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)
Check the appropriate box below if the Form 8-K filing is interprovisions:	ended to simultaneously satisfy the filing	3 obligation of the registrant under any of the following
[] Written communication pursuant to Rule 425 under the S	ecurities Act (17 CFR 230.425)	
[] Soliciting material pursuant to Rule 14a-12 under the Exc	change Act (17 CFR 240.14a-12)	
[] Pre-commencement communications pursuant to Rule 14	d-2(b) under the Exchange Act (17 CFR	240.14d-2(b))
Pre-commencement communications pursuant to Rule 13	e-4(c) under the Exchange Act (17 CFR	240.13e-4(c))
Item 7.01 Regulation FD Disclosure		
LabCorp (NYSE: LH), a leading global life sciences company (CEI), a national benchmarking survey and report on corpo workplace equality, administered by the Human Rights Campa	rate policies and practices related to le	

Exhibit 99.1

Exhibit Index

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>LABORATORY CORPORATION OF AMERICA HOLDINGS</u> Registrant

By: /s/ F. SAMUEL EBERTS III

F. Samuel Eberts III Chief Legal Officer and Secretary

November 13, 2017

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact: Pattie Kushner (media) - +1 336-436-8263

Media@labcorp.com

Scott Frommer (investors) - +1 336-436-5076

Investor@labcorp.com

Company Information: www.labcorp.com

358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171

LabCorp Earns 100 Percent on Human Rights Campaign Foundation's 16th Annual Scorecard on LGBTQ Workplace Equality

Receives Designation as a Best Place to Work for LGBTQ Equality

BURLINGTON, N.C., Nov. 13, 2017 - LabCorp (NYSE: LH), a leading global life sciences company, announced that it received a perfect score of 100 percent on the 2018 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related to lesbian, gay, bisexual, transgender and queer (LGBTQ) workplace equality, administered by the Human Rights Campaign Foundation.

"We are pleased to receive this recognition," said David P. King, chairman and CEO of LabCorp. "At LabCorp, we seek to set an unequivocal tone and standard of treating every person with dignity and respect. The CEI recognition demonstrates that our 57,000 colleagues around the globe hold each other accountable to these values and to a positive work environment and culture."

The 2018 CEI rated 947 businesses in the report, which evaluates LGBTQ-related policies and practices including non-discrimination workplace protections, domestic partner benefits, transgender-inclusive health care benefits, competency programs, and public engagement with the LGBTQ community. LabCorp's efforts in satisfying all of the CEI's criteria resulted in a 100 percent ranking and the designation as a Best Place to Work for LGBTQ Equality.

This is the first time LabCorp formally participated in the survey, achieving the highest score on its initial submission.

About the Human Rights Campaign Foundation

The Human Rights Campaign Foundation is the educational arm of America's largest civil rights organization working to achieve equality for lesbian, gay, bisexual, transgender and queer people. For more information on the 2018 Corporate Equality Index, or to download a free copy of the report, visit www.hrc.org/cei.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly \$9.5 billion for 2016. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

Forward-Looking Statements

This press release contains forward-looking statements including with respect to estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company's Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company's filings with the SEC including the information in the Company's Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.